<DOC>
	<DOCNO>NCT00042848</DOCNO>
	<brief_summary>RATIONALE : Modafinil may effective relieve fatigue patient cancer undergo chemotherapy . The effectiveness modafinil relieve chemotherapy-related fatigue yet know . PURPOSE : This randomized phase III trial study effectiveness modafinil treat fatigue patient receive chemotherapy cancer .</brief_summary>
	<brief_title>Modafinil Treating Fatigue Patients Receiving Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess degree modafinil reduce fatigue cancer patient receive chemotherapy . - Assess relationship depression fatigue patient treat drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Beginning day 5 second course chemotherapy , patient receive oral modafinil daily . - Arm II : Beginning day 5 second course chemotherapy , patient receive oral placebo daily . Treatment arm continue day 7 course 4 chemotherapy absence disease progression unacceptable toxicity . Fatigue quality life assess day 7 course 2-4 chemotherapy . PROJECTED ACCRUAL : A total 837 patient accrue study within approximately 2.5 year .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Concurrently receive previously receive chemotherapy schedule least 3 additional course chemotherapy Each course chemotherapy must least 2 week duration No concurrent radiotherapy interferon therapy Brief Fatigue Inventory question # 3 `` fatigue bad '' score 2 great 1 week first chemotherapy course PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy At least 6 month Hematopoietic Not specify Hepatic No uncontrolled anemia Renal Not specify Cardiovascular No history clinically significant cardiac disease , include follow : Unstable angina Left ventricular hypertrophy Ischemic echocardiogram change Chest pain Arrhythmia Other clinically significant manifestation mitral valve prolapse association use central nervous system stimulant ( e.g. , caffeine , amphetamine , methylphenidate ) No uncontrolled hypertension Gastrointestinal Able swallow medication No narrowing ( pathological iatrogenic ) obstruction gastrointestinal tract Other No severe headaches No glaucoma No seizure disorder No narcolepsy No psychotic disorder No Tourette 's syndrome No alcohol drug abuse Not pregnant nursing Fertile patient must use effective barrier contraception least 1 full menstrual cycle study completion PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy No concurrent chronic corticosteroid Radiotherapy See Disease Characteristics Surgery Not specify Other No prior modafinil At least 30 day since prior regular use psychostimulants ( e.g. , amphetamine , methylphenidate , pemoline ) monoamine oxidase inhibitor ( MAOIs ) No concurrent alcohol Concurrent acetaminophen codeine hydrocodone bitartrate allow Concurrent phenytoin allow Concurrent warfarin anticoagulation lowdose warfarin ( 1 mg mouth daily ) maintenance venous access device allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>fatigue</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>